Kymera Therapeutics, Inc. $KYMR Shares Acquired by Advisors Asset Management Inc.

Advisors Asset Management Inc. increased its position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 81.7% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,959 shares of the company’s stock after acquiring an additional 2,230 shares during the period. Advisors Asset Management Inc.’s holdings in Kymera Therapeutics were worth $136,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of KYMR. Wellington Management Group LLP grew its holdings in Kymera Therapeutics by 13.0% during the 1st quarter. Wellington Management Group LLP now owns 5,996,873 shares of the company’s stock valued at $164,134,000 after buying an additional 689,547 shares during the last quarter. Janus Henderson Group PLC grew its holdings in Kymera Therapeutics by 2,397.9% during the 4th quarter. Janus Henderson Group PLC now owns 377,384 shares of the company’s stock valued at $15,197,000 after buying an additional 362,276 shares during the last quarter. Vanguard Group Inc. grew its holdings in Kymera Therapeutics by 7.0% during the 1st quarter. Vanguard Group Inc. now owns 5,231,392 shares of the company’s stock valued at $143,183,000 after buying an additional 344,080 shares during the last quarter. Siren L.L.C. grew its holdings in Kymera Therapeutics by 9.1% during the 1st quarter. Siren L.L.C. now owns 3,240,313 shares of the company’s stock valued at $88,687,000 after buying an additional 270,580 shares during the last quarter. Finally, Nuveen LLC acquired a new stake in Kymera Therapeutics during the 1st quarter valued at $3,920,000.

Kymera Therapeutics Trading Up 1.7%

KYMR stock opened at $46.99 on Friday. The stock has a 50-day moving average price of $43.40 and a two-hundred day moving average price of $37.28. Kymera Therapeutics, Inc. has a 12-month low of $19.44 and a 12-month high of $53.27. The company has a market cap of $3.36 billion, a PE ratio of -13.54 and a beta of 2.17.

Kymera Therapeutics (NASDAQ:KYMR) last posted its quarterly earnings results on Monday, August 11th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.12). Kymera Therapeutics had a negative net margin of 616.03% and a negative return on equity of 31.60%. The firm had revenue of $11.48 million for the quarter, compared to analysts’ expectations of $17.37 million. During the same period last year, the firm posted ($0.58) EPS. Kymera Therapeutics’s revenue was down 55.1% on a year-over-year basis. Equities analysts forecast that Kymera Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.

Insider Transactions at Kymera Therapeutics

In other news, Director Bvf Partners L. P/Il purchased 317,167 shares of the stock in a transaction on Monday, June 30th. The stock was purchased at an average price of $44.00 per share, with a total value of $13,955,348.00. Following the completion of the transaction, the director owned 2,798,795 shares in the company, valued at approximately $123,146,980. The trade was a 12.78% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Bros. Advisors Lp Baker purchased 655,500 shares of the stock in a transaction on Monday, June 30th. The shares were purchased at an average cost of $44.00 per share, with a total value of $28,842,000.00. Following the transaction, the director owned 6,117,295 shares of the company’s stock, valued at $269,160,980. This trade represents a 12.00% increase in their position. The disclosure for this purchase can be found here. 16.01% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of equities research analysts have commented on KYMR shares. Stifel Nicolaus started coverage on Kymera Therapeutics in a report on Tuesday, May 20th. They set a “buy” rating and a $55.00 target price on the stock. Oppenheimer reiterated an “outperform” rating and set a $53.00 target price (down previously from $56.00) on shares of Kymera Therapeutics in a report on Friday, June 27th. Wells Fargo & Company lowered their target price on Kymera Therapeutics from $57.00 to $53.00 and set an “overweight” rating on the stock in a report on Thursday, June 26th. Jefferies Financial Group set a $64.00 target price on Kymera Therapeutics and gave the company a “buy” rating in a report on Wednesday, June 25th. Finally, Guggenheim restated a “buy” rating and set a $60.00 price objective on shares of Kymera Therapeutics in a report on Tuesday, June 3rd. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $58.76.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.